WDR5, a member of the WD repeat protein family, plays a crucial role in chromatin remodeling and gene regulation through its involvement in the assembly of histone-modifying complexes. Functionally, WDR5 serves as a core component of the MLL (mixed-lineage leukemia) histone methyltransferase complex, which catalyzes the methylation of histone H3 at lysine 4 (H3K4), a mark associated with active transcription. By facilitating the recruitment of MLL complexes to specific genomic loci, WDR5 contributes to the establishment of transcriptionally permissive chromatin states, promoting gene activation and expression. Additionally, WDR5 interacts with other chromatin-modifying enzymes and transcription factors, further modulating gene expression patterns and cellular processes such as cell cycle progression, differentiation, and development. Through its role in chromatin remodeling and transcriptional regulation, WDR5 exerts significant influence over diverse biological processes critical for cellular function and organismal development.
The activation of WDR5 involves intricate regulatory mechanisms aimed at promoting its association with histone-modifying complexes and facilitating chromatin remodeling events. Various post-translational modifications, such as phosphorylation and acetylation, regulate the activity and function of WDR5. Phosphorylation of WDR5 by specific kinases can enhance its interaction with other components of the MLL complex, thereby promoting the assembly and activation of histone methyltransferase activity. Additionally, cellular signaling pathways and transcriptional regulators may modulate WDR5 activity by regulating its expression levels or subcellular localization. Furthermore, protein-protein interactions between WDR5 and other chromatin-modifying enzymes or transcription factors contribute to the formation of multiprotein complexes involved in gene activation. Understanding the detailed mechanisms underlying WDR5 activation provides insights into the regulation of chromatin structure and gene expression dynamics, offering avenues for intervention in diseases characterized by dysregulated gene expression patterns.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
NSC 66811 | 6964-62-1 | sc-311507 sc-311507A | 10 mg 50 mg | $162.00 $683.00 | ||
NSC 66811 is a chemical compound that indirectly activates WDR5 by promoting histone acetylation through the inhibition of histone deacetylases (HDACs). By inhibiting HDACs, NSC 66811 increases histone acetylation, facilitating the recruitment of WDR5 to chromatin and promoting the formation of active histone methyltransferase complexes. | ||||||
UNC 1215 | 1415800-43-9 | sc-475020 | 10 mg | $380.00 | ||
UNC1215 is a small molecule inhibitor that indirectly activates WDR5 by inhibiting the interaction between WDR5 and MLL complexes. Inhibition of this interaction influences downstream targets, including WDR5. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
This compound, also called CHIR-99021 is a small molecule inhibitor of glycogen synthase kinase 3 beta (GSK-3β), indirectly activating WDR5 by influencing the Wnt/β-catenin pathway. Inhibition of GSK-3β affects downstream targets, including WDR5. | ||||||
WAY 262611 | sc-397019 sc-397019A | 5 mg 25 mg | $131.00 $520.00 | 2 | ||
WAY-262611 is a small molecule inhibitor that indirectly activates WDR5 by inhibiting the interaction between WDR5 and MLL complexes. Inhibition of this interaction influences downstream targets, including WDR5. | ||||||
JW 55 | 664993-53-7 | sc-364517 sc-364517A | 10 mg 50 mg | $172.00 $726.00 | ||
JW 55 is a small molecule inhibitor of the Wnt pathway, indirectly activating WDR5 by modulating Wnt signaling. By inhibiting the Wnt pathway, JW 55 influences downstream targets, including WDR5. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
GSK-3 Inhibitor IX is a small molecule inhibitor of glycogen synthase kinase 3 beta (GSK-3β), indirectly activating WDR5 by influencing the Wnt/β-catenin pathway. Inhibition of GSK-3β affects downstream targets, including WDR5. | ||||||
β-Catenin/Tcf Inhibitor, FH535 | 108409-83-2 | sc-221398 sc-221398A | 10 mg 50 mg | $182.00 $374.00 | 7 | |
FH535 is a small molecule inhibitor of the Wnt pathway, indirectly activating WDR5 by modulating Wnt signaling. By inhibiting the Wnt pathway, FH535 influences downstream targets, including WDR5. | ||||||